

AXIRON[®] MARKETING AUTHORISATION GRANTED IN CANADA

Acrux (ASX: ACR) today reported that Eli Lilly has received approval to market Axiron[®] in Canada, the first market outside the United States. Health Canada has granted Lilly a marketing authorisation for Axiron as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

Acrux expects to begin earning royalties on net sales of Axiron in Canada during the 2012/13 financial year. Regulatory decisions on marketing applications under review in Australia and select European countries are anticipated during 2012.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products marketed by licensees in the USA, two products approved in Europe, one product in registration in the USA and further products at earlier stages of development.